INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. – PLRX
Pliant Therapeutics, Inc. (PLRX)
Company Research
Source: GlobeNewswire
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc (“Pliant” or the “Company”) (NASDAQ: PLRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Pliant and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On February 7, 2025, Pliant issued a press release “announc[ing] that following a prespecified data review and recommendations by the trial’s independent Data Safety Monitoring Board (DSMB), the Company has voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis (IPF).” Following this news, Wells Fargo and Citi analysts both downgraded Pliant, citing uncertainty about bexotegrast’s path forward. On t
Show less
Read more
Impact Snapshot
Event Time:
PLRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PLRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PLRX alerts
High impacting Pliant Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PLRX
News
- Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid TumorsGlobeNewswire
- Pliant Therapeutics to Participate in the Piper Sandler Healthcare ConferenceGlobeNewswire
- Pliant Therapeutics (NASDAQ:PLRX) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=PLRX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreeMarketBeat
- Pliant Therapeutics (NASDAQ:PLRX) had its price target lowered by analysts at Royal Bank Of Canada from $3.00 to $2.00. They now have a "sector perform" rating on the stock.MarketBeat
- Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial ResultsGlobeNewswire
PLRX
Earnings
- 11/6/25 - Beat
PLRX
Sec Filings
- 12/22/25 - Form 3
- 12/16/25 - Form 8-K
- 12/8/25 - Form 8-K
- PLRX's page on the SEC website